Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Philippe Jaquet"'
Autor:
Jesse Z. Dong, Michael D. Culler, Federica Barbieri, John E. Taylor, Leo J. Hofland, Marily Theodoropoulou, Henry Dufour, Philippe Jaquet, Tullio Florio, Alexandru Saveanu, Jacques-Pierre Moreau, Peter M. van Koetsveld, Renato Spaziante, Richard A Feelders, Günter K. Stalla, Ginette Gunz, Gianluigi Zona
Publikováno v:
Endocrine-Related Cancer
Endocrine-Related Cancer, BioScientifica, 2008, 15 (2), pp.583-96. ⟨10.1677/ERC-07-0271⟩
Endocrine-Related Cancer, 15(2), 583-596. Bioscientifica Ltd
Endocrine-Related Cancer, 2008, 15 (2), pp.583-96. ⟨10.1677/ERC-07-0271⟩
Endocrine-Related Cancer, BioScientifica, 2008, 15 (2), pp.583-96. ⟨10.1677/ERC-07-0271⟩
Endocrine-Related Cancer, 15(2), 583-596. Bioscientifica Ltd
Endocrine-Related Cancer, 2008, 15 (2), pp.583-96. ⟨10.1677/ERC-07-0271⟩
International audience; Dopamine D2 and somatostatin receptors (sstrs) were reported to affect non-functioning pituitary adenoma (NFPA) proliferation in vitro. However, the reported results differ according to the experimental conditions used. We est
Autor:
Anne Barlier, Philippe Jaquet
Publikováno v:
European Journal of Endocrinology. 154:187-195
Hyperprolactinaemia is characterised by gonadal dysfunction, including infertility and reduced libido and, if left untreated, is associated with an increased risk of long-term complications, such as osteoporosis. The first-line therapy for patients w
Autor:
Jean Marc Kuhn, Philippe Jaquet, Frederic Castinetti, Jean Régis, Thierry Brue, Henry Dufour, Bernard Conte-Devolx, David Taïeb, Manabu Tamura, Philippe Chanson
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 90:4483-4488
Because surgical and medical therapies of acromegaly all have specific limitations, radiotherapy has been used as an adjunctive strategy. Stereotactic radiosurgery has not yet been widely evaluated.The objective was to perform an analysis of long-ter
Autor:
A. Zamora, Philippe Jaquet, Alain Enjalbert, Anne Barlier, G. Gunz, I. Morange-Ramos, I Pellegrini-Bouiller, H. Dufour, Dominique Figarella-Branger, Michel Grino
Publikováno v:
Journal of Neuroendocrinology. 11:491-502
We examined the expression of functional growth hormone secretagogue receptors (GHS-R) in a series of 30 human pituitary adenomas-six secreting GH, three GH-PRL, six prolactin (PRL), five adrenocorticotrophic hormone (ACTH), one thyroid stimulating h
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 82:18-22
Somatostatin analogs are an alternative treatment to pituitary surgery and radiotherapy in acromegalic patients. Recently, a depot long-lasting formulation of slow release (SR) lanreotide has been shown to be effective in the short-term control of GH
Autor:
L. Simionescu, Peter Grass, Michael C. Sheppard, S. W. J. Lamberts, G. Pagani, Philippe Jaquet, Hans Ørskov, Ioana Lancranjan, P. Kendall-Taylor, C. Bruns, Jak Jervell, Peter Marbach
Publikováno v:
Metabolism. 45:67-71
A stable and sustained suppression of growth hormone (GH) secretion was noted in 101 patients treated long term with individual doses (20 and 30 mg in 89 patients, 40 mg in 12 patients) of Sandostatin LAR (Sandoz Pharma Ltd, Basel, Switzerland). Dose
Autor:
C. Bruns, Ioana Lancranjan, Hans Ørskov, L. Simionescu, S. W. J. Lamberts, G. Pagani, Peter Marbach, Peter Grass, Philippe Jaquet, Jak Jervell, P. Kendall-Taylor, Michael C. Sheppard
Publikováno v:
Metabolism. 44:18-26
Sandostatin LAR® was developed by incorporating octreotide in microspheres of the biodegradable polymer poly( dl -lactide-coglycolide glucose). One hundred acromegalics, 85 of whom were known to be “responders” to octreotide (subcutaneous [SC] S
Autor:
Philippe Jaquet, Jérôme Bertherat, Claude Kordon, Françoise Peillon, Philippe Chanson, Alain Enjalbert, Didier Dewailly, Jacques Epelbaum, José Timsit
Publikováno v:
Hormone Research. 38:94-99
The development of a long-acting somatostatin (SRIH) analog (octreotide, Sandoz) has been a major breakthrough in the treatment of acromegaly. However, in 20-30% of the patients, growth hormone (GH) plasma levels remain elevated (> 10 micrograms/l) d